Scottish Health Innovations Ltd (SHIL) works in partnership with NHS Scotland to identify, protect, develop and commercialise new innovations from healthcare professionals. Registered Number: SC 236303. Registered address: The Golden Jubliee National Hospital, Fourth Floor East, Agmemmon St, Clydebank, G81 4DY
Aurum Biosciences Ltd is a biopharmaceutical company developing novel oxygen carriers and proprietary software for use with MRI, initially for Acute Ischaemic Stroke (AIS). Follow-on indications include heart disease, cancer, epilepsy, and dementia. Aurum is currently taking a stroke management product (“GOLD”) through preclinical development and into clinical studies of efficacy and safety.
Aurum develops novel pharmaceuticals for use in several different clinical indications of high unmet medical need. Follow-on programmes include products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke. Aurum has funding in place to initiate recruitment for a Phase 2 clinical study in stroke patients.
Aurum raises £670k as part of a new round of equity funding
ABL-101 Found to be a Promising Candidate for Use in Inflammation Imaging
Aurum Biosciences Has Second Patent Granted in the EU
Aurum Publishes Paper on ABL-101 Technology
Aurum Biosciences receives UK regulatory approval for a Phase 2 trial of ABL-101 in stroke patients
Aurum Biosciences is delighted to announce that Dr Jo Bhattacharaya has joined the Scientific Advisory Board
Aurum Biosciences is delighted to announce that Elaine Ferguson has joined us as our Chief Financial Officer
Aurum Invited to London Stock Exchange by Minister for Life Sciences
Members of the Scottish Parliament Welcome Investment in Aurum Biosciences Ltd, a Spin Out Company of NHSGGC and the University of Glasgow
Aurum Biosciences raises £3M ($4.5M) from investors in UK and USA and signs strategic US partnership
Aurum Biosciences has Patent Granted in the United States
“SHIL has been working with Aurum Biosciences for over five years following the successful spin-out from NHS Greater Glasgow and Clyde and the University of Glasgow. Significant progress has been made in advancing the diagnosis and treatment of stroke with promising results evident in pre-clinical trials. This is vital work; in Scotland alone stroke remains the third biggest killer and the leading cause of disability. This new investment from SHIL and other investors, combined with ambitious development plans, will support the team to extend their work in stroke, and other conditions; with the ultimate aim of saving and improving lives."